J Coll Physicians Surg Pak:过敏性鼻炎患者中,常见过敏原的皮刺试验反应研究

2018-10-14 AlexYang MedSci原创

最近,有研究人员鉴定了在过敏性鼻炎患者中,引起过敏症状的常见过敏原。研究是一个代表性的研究。包括了那些临床诊断为过敏性鼻炎的患者。研究人员对这些患者进行了皮刺试验(SPT),使用了12中常见的气源性过敏原。试验中包括了阳性对照和阴性对照,并记录了处理15分钟后的结果,并将水泡直径大于3毫米作为阳性反应。研究发现,在130名患者中,78(60%)名为男性,52(40%)名为女性。对任何一种过敏原敏感

最近,有研究人员鉴定了在过敏性鼻炎患者中,引起过敏症状的常见过敏原。研究是一个代表性的研究。包括了那些临床诊断为过敏性鼻炎的患者。研究人员对这些患者进行了皮刺试验(SPT),使用了12中常见的气源性过敏原。试验中包括了阳性对照和阴性对照,并记录了处理15分钟后的结果,并将水泡直径大于3毫米作为阳性反应。

研究发现,在130名患者中,78(60%)名为男性,52(40%)名为女性。对任何一种过敏原敏感的比例为90%。102名(78%)患者中对过敏原敏感不少于2种,并且20%的患者对不少于6种的过敏原敏感。最常见的室内和室外过敏原分别为肉桂属植物(50.7%)和粉尘螨(42.3%)。狗毛和曲霉菌为最不常见的过敏原(13.8%)。

最后,研究人员指出,他们的研究强调了对任何一种过敏原过敏的频率上升,并且对树木草过敏明显,尤其是肉桂属和大麻属植物。同时,研究人员也指出,室内过敏原-粉尘螨的敏感流行度也在上升。

原始出处:

Saleem N, Waqar S, Shafi A et al. Skin Prick Test Reactivity to Common Aeroallergens among Allergic Rhinitis Patients. J Coll Physicians Surg Pak. Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783338, encodeId=5ea91e8333895, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Fri Jan 18 04:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047029, encodeId=44e7204e02904, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jun 01 10:06:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076972, encodeId=8c0020e6972da, content=<a href='/topic/show?id=ab39e1948fb' target=_blank style='color:#2F92EE;'>#皮刺试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71948, encryptionId=ab39e1948fb, topicName=皮刺试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Thu Nov 01 18:06:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350064, encodeId=833f35006442, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:25 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442619, encodeId=504014426193d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 16 13:06:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
    2019-01-18 waiwai3030
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783338, encodeId=5ea91e8333895, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Fri Jan 18 04:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047029, encodeId=44e7204e02904, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jun 01 10:06:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076972, encodeId=8c0020e6972da, content=<a href='/topic/show?id=ab39e1948fb' target=_blank style='color:#2F92EE;'>#皮刺试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71948, encryptionId=ab39e1948fb, topicName=皮刺试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Thu Nov 01 18:06:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350064, encodeId=833f35006442, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:25 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442619, encodeId=504014426193d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 16 13:06:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783338, encodeId=5ea91e8333895, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Fri Jan 18 04:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047029, encodeId=44e7204e02904, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jun 01 10:06:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076972, encodeId=8c0020e6972da, content=<a href='/topic/show?id=ab39e1948fb' target=_blank style='color:#2F92EE;'>#皮刺试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71948, encryptionId=ab39e1948fb, topicName=皮刺试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Thu Nov 01 18:06:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350064, encodeId=833f35006442, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:25 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442619, encodeId=504014426193d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 16 13:06:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783338, encodeId=5ea91e8333895, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Fri Jan 18 04:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047029, encodeId=44e7204e02904, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jun 01 10:06:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076972, encodeId=8c0020e6972da, content=<a href='/topic/show?id=ab39e1948fb' target=_blank style='color:#2F92EE;'>#皮刺试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71948, encryptionId=ab39e1948fb, topicName=皮刺试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Thu Nov 01 18:06:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350064, encodeId=833f35006442, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:25 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442619, encodeId=504014426193d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 16 13:06:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]
    2018-10-21 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1783338, encodeId=5ea91e8333895, content=<a href='/topic/show?id=f16a499652' target=_blank style='color:#2F92EE;'>#Coll#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4996, encryptionId=f16a499652, topicName=Coll)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Fri Jan 18 04:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047029, encodeId=44e7204e02904, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jun 01 10:06:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076972, encodeId=8c0020e6972da, content=<a href='/topic/show?id=ab39e1948fb' target=_blank style='color:#2F92EE;'>#皮刺试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71948, encryptionId=ab39e1948fb, topicName=皮刺试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Thu Nov 01 18:06:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350064, encodeId=833f35006442, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 21 12:29:25 CST 2018, time=2018-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442619, encodeId=504014426193d, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Oct 16 13:06:00 CST 2018, time=2018-10-16, status=1, ipAttribution=)]

相关资讯

Allergy Asthma Clin Immunol:5种草花粉提取混合物舌下免疫治疗的观察性群体研究

过敏性鼻炎影响着西方欧洲人口群体的四分之一之多。预防过敏源免疫疗法在减少急性症状发作(花粉过敏)中是有效的。到目前为止,一种5种草花粉提取混合物舌下免疫治疗(5GPE-SLIT)被用来治疗花粉过敏的过敏性鼻炎。最近,有研究人员描述了真实世界中5GPE-SLIT的治疗情况。研究包括了280名成年人和203名儿童。处方信息包括了82.5%的成年人和86.7%的儿童。研究人员对所有的患者进行了皮刺测试。

八成哮喘患者都有这个病 而这个病几乎谁都逃不过

进入秋季,一早一晚天气开始变凉,此时正处于季节交替的时候。今天上午定焦大叔来到首都儿科研究所的哮喘科,医院楼道里站满了等待就诊的孩子和家长。11诊室,正在出诊的是哮喘科刘传合医生。刘医生正在给一位小女孩听诊,电脑前另一位年轻医生飞快地记录着孩子的病例。

Int Forum Allergy Rhinol:双倍剂量鼻内皮质类固醇对过敏性鼻炎作用研究

当标准剂量的鼻内皮质类固醇(INCS)不能够有效的控制过敏性鼻炎(AR)时,双倍剂量的INCS是可以选择的。最近,有研究人员系统性的评估了双倍剂量的INCS对过敏性鼻炎的影响。研究人员在MEDLINE和EMBASE中进行文献搜索,筛选出了那些包括双倍剂量INCS和单倍剂量INCS治疗AR患者效果对比的研究。研究发现,总共有12个研究(4166名患者)符合入选标准。其中有5个是儿科研究(1868名患

Aust J Gen Pract:增殖腺扁桃体切除术后,伴随残余打鼾和睡眠症状儿童过敏性鼻炎发生率研究

在儿童中,过敏性鼻炎对睡眠障碍呼吸(SDB)具有贡献性作用。尽管增殖腺扁桃体切除术经常用来治疗SDB,一些患者仍旧会伴随残余的睡眠症状并回诊。最近,有研究人员在经历增殖腺扁桃体切除术的儿童中通过放射变应性吸附法测试(RAST)对过敏性鼻炎的发生率进行评估,这些儿童均具有残余的打鼾或者睡眠障碍现象。研究是一个回顾性的研究,包括了500名增殖腺扁桃体切除术术后的儿童。研究人员评估和记录了残余的打鼾、睡

BMC Pulm Med:过去20年哮喘、鼻炎和呼吸系统症状流行度变化

最近,有研究人员调查了过去20年成年人中呼吸道症状和障碍以及与之相关的出生时间、生活方式和睡眠相关变量的变化情况。研究包括了6085名女性和5184名男性,年龄在20-44岁之间,他们随机选自北欧7个中心,并且跟踪调查了20年。参与第一次调查的参与者数量达到了21595名,并且11269名参与了所有的3项调查。参与者被分成了3个出生年龄段:1944-1955, 1956-1965和1966-197

过敏性鼻炎高发季节 该如何照顾你的鼻子?

季节交替,过敏性鼻炎开始困扰很多患者,今天我们就大家关心的一些有关过敏性鼻炎的问题给予解答。